EUVIMEDEUVIMED entdecken
Multizentrische Studie

RECIP 1.0 Predicts Progression-Free Survival After [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Andrei Gafita, Loic Djaileb, Isabel Rauscher, Wolfgang P Fendler, Boris Hadaschik, Steven P Rowe, Ken Herrmann, Lilja B Solnes, Jeremie Calais, Matthew B Rettig, Manuel Weber, Andrea Farolfi und 2 weitere

Journal of Nuclear Medicine · 2024-06 · 65 (6) · 917-922

DOI: 10.2967/jnumed.123.267234 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 18.04.2024. Verfasst von Andrei Gafita und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University Scho…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Radiopharmaceuticals, Lutetium, Neoplasm Metastasis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Response Evaluation Criteria in Prostate-Specific Membrane Antigen Imaging (RECIP) 1.0 is an evidence-based framework to evaluate therapeutic efficacy in metastatic prostate cancer using prostate-specific membrane antigen (PSMA) PET/CT. This study aimed to evaluate the associations of interim PSMA PET/CT by RECIP 1.0 with short-term outcome after radiopharmaceutical treatment.

Methods

This multicenter retrospective study included patients with metastatic castration-resistant prostate cancer who underwent [177Lu]Lu-PSMA radiopharmaceutical therapy at 3 academic centers and received PSMA PET/CT at baseline and at 12 wk. Pairs of PSMA PET/CT images were assessed by 5 readers for visual RECIP 1.0. The primary outcome was the association of RECIP with prostate-specific antigen progression-free survival (PSA-PFS) by Kaplan-Meier analysis.

Results

In total, 124 of 287 screened patients met the inclusion criteria, with 0 (0%), 29 (23%), 54 (44%), and 41 (33%) of those 124 patients having complete response, partial response, stable disease, or progressive disease (PD) by visual RECIP 1.0, respectively. Patients with visual RECIP PD had a significantly shorter PSA-PFS than those with RECIP stable disease or with RECIP partial response (2.6 vs. 6.4 vs. 8.4 mo; P < 0.001). The median PSA-PFS among patients with RECIP PD versus those with non-RECIP PD was 2.6 versus 7.2 mo (hazard ratio, 13.0; 95% CI, 7.0-24.1; P < 0.001).

Conclusion

PSMA PET/CT by RECIP 1.0 after 2 cycles of [177Lu]Lu-PSMA is prognostic for PSA-PFS. PSMA PET/CT by RECIP 1.0 may be used in earlier stages of prostate cancer to evaluate drug efficacy and to predict progression-free survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantRadiopharmaceuticalsLutetiumNeoplasm MetastasisProgression-Free SurvivalPositron Emission Tomography Computed TomographyHumansMaleAgedRetrospective StudiesMiddle AgedAged, 80 and overGlutamate Carboxypeptidase IIProstate-Specific AntigenAntigens, SurfaceTreatment OutcomeHeterocyclic Compounds, 1-RingRadioisotopes

Stichwörter der Autor:innen

LuPSMAPSMA PETRECIPmetastatic castration-resistant prostate cancerradiopharmaceutical therapyresponse evaluation

Substanzen

RadiopharmaceuticalsLutetiumLutetium-177Glutamate Carboxypeptidase IIPluvictoProstate-Specific AntigenAntigens, SurfaceFOLH1 protein, humanHeterocyclic Compounds, 1-RingRadioisotopes

Autor:innen und Institutionen

  • Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; agafita1@jhmi.edu.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • LRB, Nuclear Medicine Department, CHU Grenoble Alpes, INSERM, Université Grenoble Alpes, Grenoble, France.
  • Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Urology, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Zitieren

APA

Gafita, A., Djaileb, L., Rauscher, I., Fendler, W. P., Hadaschik, B., Rowe, S. P., Herrmann, K., Solnes, L. B., Calais, J., Rettig, M. B., Weber, M., Farolfi, A., Benz, M. R., & Eiber, M. (2024). RECIP 1.0 Predicts Progression-Free Survival After [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 65(6), 917-922. https://doi.org/10.2967/jnumed.123.267234

Vancouver

Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, et al. RECIP 1.0 Predicts Progression-Free Survival After [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2024;65(6):917-922. doi:10.2967/jnumed.123.267234

BibTeX
@article{Gafita2024,
  author = {Gafita, Andrei and Djaileb, Loic and Rauscher, Isabel and Fendler, Wolfgang P and Hadaschik, Boris and Rowe, Steven P and Herrmann, Ken and Solnes, Lilja B and Calais, Jeremie and Rettig, Matthew B and Weber, Manuel and Farolfi, Andrea and Benz, Matthias R and Eiber, Matthias},
  title = {RECIP 1.0 Predicts Progression-Free Survival After [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {6},
  pages = {917--922},
  doi = {10.2967/jnumed.123.267234}
}
Kostenlos starten →